Gilead's Viread approved in US for chronic hepatitis B
This article was originally published in Scrip
Gilead Sciences' oral anti-HIV drug Viread (tenofovir disoproxil fumarate) has been approved for the treatment of chronic hepatitis B in adults by the USFDA.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.